Kezar Life Sciences Inc

Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer in South San Francisco and California. Its product pipeline include KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J. Kirk, and Jack Taunton on February 20, 2015 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer. Its product pipeline includes KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J. Kirk, and Jack Taunton on February 20, 2015 and is headquartered in South San Francisco, CA.

Kezar Life Sciences: Key Catalysts Ahead

SAN FRANCISCO, May  04, 2020  (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced the appointment of Noreen R. Henig, MD as its Chief Medical Officer. As an integral member of the Company’s Executive Leadership team, Dr. Henig will oversee all aspects of the Company’s clinical development, regulatory and medical affairs.

Kezar Life Sciences Strengthens Executive Team with the Appointment of Noreen R. Henig, MD as Chief Medical Officer

SOUTH SAN FRANCISCO, Calif., April  09, 2020  (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today issued the following statement regarding the COVID-19 pandemic:

Kezar Provides Statement Regarding COVID-19 Pandemic

Is  (KZR) Outperforming Other Medical Stocks This Year?

Is Kezar Life Sciences (KZR) Stock Outpacing Its Medical Peers This Year?

SOUTH SAN FRANCISCO, Calif., Feb.  26, 2020  (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced its Chief Executive Officer, John Fowler, will present a corporate overview at Cowen and Company’s 40th Annual Healthcare Conference on Tuesday, March 3, 2020 at 12:00pm EST in Boston, MA.

Kezar Life Sciences to Present at Cowen and Company’s 40th Annual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Feb.  04, 2020  (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmune disease and cancer, today announced the closing of an underwritten public offering of 16,115,385 shares of its common stock, and to certain investors in lieu thereof, pre-funded warrants to purchase 2,884,615 shares of its common stock at an exercise price of $0.001 per share. The public offering price of each share of common stock was $2.60 and the public offering price of each pre-funded warrant was $2.599. In addition, Kezar granted to the underwriters an option to purchase up to an additional 2,850,000 shares of common stock, which the Underwriters exercised in full.

Kezar Announces Closing of $56.8 Million Public Offering of Common Stock and Pre-Funded Warrants

Aurora Mobile Ltd - ADR

Wall Street sell-side analysts recommend buying shares of Aurora Mobile Limited (NASDAQ:JG) and Kezar Life Sciences Inc (NASDAQ:KZR), two falling knives whose share prices lost more than 59% over the past 52 weeks through Feb.

Wall Street Recommends Picking Up These Falling Knives

SOUTH SAN FRANCISCO, Calif., Jan.  31, 2020  (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq:  KZR ), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmune disease and cancer, today announced the pricing of an underwritten public offering of 16,115,385 shares of its common stock, and to certain investors in lieu thereof, pre-funded warrants to purchase 2,884,615 shares of its common stock at an exercise price of $0.001 per share. The public offering price of each share of common stock is $2.60 and the public offering price of each pre-funded warrant is $2.599. In addition, Kezar has granted the underwriters a 30-day option to purchase additional shares of common stock of up to 15% of the aggregate number of shares of common stock plus the shares of common stock underlying the pre-funded warrants being offered in the offering. The offering is expected to close on February 4, 2020, subject to customary closing conditions.

Kezar Announces Pricing of $49.4 Million Public Offering of Common Stock and Pre-Funded Warrants

SOUTH SAN FRANCISCO, Calif., Jan.  30, 2020  (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmune disease and cancer, today announced that it intends to offer and sell shares of its common stock and, to certain investors in lieu thereof, pre-funded warrants to purchase shares of its common stock, in an underwritten public offering. All of the securities in the offering will be sold by Kezar. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

Kezar Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

SOUTH SAN FRANCISCO, Calif., Dec.  19, 2019  (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq:  KZR ), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmune disease and cancer, today announced the appointment of Elizabeth Garner, MD, MPH to its Board of Directors. Dr. Garner is currently the Chief Medical Officer of ObsEva SA.

Kezar Life Sciences Enhances Clinical Expertise with the Appointment of Elizabeth Garner, MD, MPH to its Board of Directors

SOUTH SAN FRANCISCO, Calif., Oct.  01, 2019  (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq:  KZR ), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced four poster presentations at the upcoming 2019 ACR/ARP Annual Meeting taking place from November 8-13, 2019 in Atlanta, GA.  

Kezar Life Sciences Announces Presentations of Four Abstracts at the 2019 ACR/ARP Annual Meeting

SOUTH SAN FRANCISCO, Calif., Sept.  27, 2019  (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced that John Fowler, Chief Executive Officer, will be providing a corporate and strategic update at the 2019 Cantor Global Healthcare Conference in New York, NY on Thursday, October 3 at 4:10pm EDT.  

Kezar Life Sciences to Present at the 2019 Cantor Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Aug.  28, 2019  (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced that members of the senior management team will present a corporate update during two upcoming investor conferences. The details of the presentations are as follows:

Kezar Life Sciences Announces Presentations at Upcoming Investor Conferences

Shares of Kezar Life Sciences Inc (NASDAQ: KZR) have retreated to a fresh 52-week low on roughly five times their average volume.

Micro-Cap Biotech Kezar Life Sciences Trades Sharply Lower On New Data

Kezar Life Sciences Inc. shares were absolutely crushed on Tuesday after the firm revealed data from its midstage trial in patients with systemic lupus erythematosus (SLE).

Is This Kezar Life Sciences Lupus Study in Trouble?

News for Kezar Life Sciences Inc Stock (KZR)